Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.
Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor kcyB (NF-kcyB) and Extracellular Signal-regulated kinase 1 and 2 (ERK1/2) and Mitogen Stress activated kinase 1 (MSK1) signaling.
The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail?
Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β-treated multiple sclerosis patients.
A study comparing the effectiveness and safety of teriflunomide and interferon beta-1a in patients with relapsing multiple sclerosis (TENERE)
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.
Randomized trial of oral teriflunomide for relapsing multiple sclerosis.
Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis.
Interleukin-1beta promotes repair of the CNS.
Brain reserve against physical disability progression over 5 years in multiple sclerosis.
Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients.
Extracellular Cues Influencing Oligodendrocyte Differentiation and (Re)myelination.
Anti-Human Herpesvirus 6A/B IgG Correlates with Relapses and Progression in Multiple Sclerosis.
Birth Outcomes in Newborns Fathered by Men with Multiple Sclerosis Exposed to Disease-Modifying Drugs.
TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab.
17 beta-estradiol inhibits cytokine, chemokine, and chemokine receptor mRNA expression in the central nervous system of female mice with experimental autoimmune encephalomyelitis.
Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study.
A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.
Antibody to α4 integrin suppresses natural killer cells infiltration in central nervous system in experimental autoimmune encephalomyelitis.
Primary results of DECIDE: a randomized, double-blind, double-dummy, active-controlled trial of daclizumab HYP vs. Interferon β-1a in RRMS patients
B1 cells are unaffected by immune modulatory treatment in remitting-relapsing multiple sclerosis patients.
Mechanism of action of mitoxantrone.
The differential diagnosis of neurological diseases by fractionating electrophoretically the CSF gamma-globulins.
Dimethyl fumarate attenuates experimental autoimmune neuritis through the nuclear factor erythroid-derived 2-related factor 2/hemoxygenase-1 pathway by altering the balance of M1/M2 macrophages.
Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study.

Pages